

Neurotech CEO to Present at Bioshares Conference

Neurotech International Limited (ASX: NTI) ("Neurotech" or "the Company") is pleased to announce that CEO Dr Alexandra Andrews will be presenting at the 16th Bioshares Biotech Summit <http://www.bioshares.com.au/albury2022.htm> in Albury, NSW at 11.00am AEST on 12 May 2022.

The unique format of the Bioshares Biotech Summit connects biotech companies with the stock market, to explore not only what biotech companies are doing, but more importantly how they are doing it. In line with this purpose, Dr. Andrews' presentation will focus on Neurotech's progress in developing and commercialising neurological solutions to improve quality of life. Dr. Andrews will discuss the recent advancements in Neurotech's landmark paediatric autism spectrum disorder (ASD) study at Monash Children's Hospital, utilising the treatment NTI164.

A copy of the presentation is attached.

Authority

This announcement has been authorised for release by the Chairman of Neurotech International Limited.

Further Information

Dr Alexandra Andrews
CEO

aa@neurotechinternational.com

+61 (0)405 339 788

Brian Leedman
Chairman

b.leedman@neurotechinternational.com

+61 (0)41 228 1780

Media:

Amalie Schreurs

White Noise Communications

amalie@whitenoisecomms.com

+61 (0)431 636 033

About Neurotech

Neurotech International Limited is a medical device and solutions company conducting clinical studies to assess the neuro-protective, anti-inflammatory and neuro-modulatory activities of our proprietary NTI/Dolce cannabis strains. Neurotech has submitted key provisional patents relating to the composition and use of NTI164 for the treatment of a range of neurological disorders including ASD. Neurotech is also commercialising Mente, the world's first home therapy that is clinically proven to increase engagement and improve relaxation in autistic children with elevated Delta band brain activity. For more information about Neurotech and Mente Autism please visit <http://www.neurotechinternational.com>



Improving Lives



Investor Presentation

May 2022

Dr Alexandra Andrews

PhD Neuroscience, BMed Sci (Hons1st)
Chief Executive Officer

Disclaimer



IMPORTANT INFORMATION

Purpose of presentation: This presentation (including this document, any related video or oral presentation, any question and answer session and any written or oral material discussed or distributed in relation to this presentation) has been prepared by Neurotech International Limited (ACN 610 205 402) (Neurotech or Company). It has been prepared for the sole purpose of providing general information on Neurotech and its business.

Not an offer or solicitation: This presentation is not investment advice nor an offer to subscribe for securities or otherwise invest in Neurotech, and it should not be relied upon to make any investment decision. Further, it does not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of securities pursuant to this presentation in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful under applicable law, including the Securities Act of 1933 (USA), as amended (US Securities Act). Securities have not been registered under the US Securities Act or any US state securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from registration under the US Securities Act and applicable state securities laws.

Not a prospectus: This presentation is not a prospectus, product disclosure statement or other investment disclosure document, and the level of disclosure in this presentation is less than such disclosure documents. It has not been lodged with any regulatory or supervisory body. This presentation does not purport to contain all of the information that a prospective investor may require to make an evaluation of Neurotech or its business activities and nothing in this presentation is, or is intended to be, a recommendation to invest in Neurotech. Neurotech does not purport to give financial or investment advice. Account has not been taken of the objectives, financial situation or needs of any recipient of this presentation.

Forward-looking statements: This presentation contains forward-looking statements which may be predictive in nature and incorporate an element of uncertainty or risk, such as 'intends', 'may', 'could', 'believes', 'estimates', 'targets' or 'expects'. These statements are based on an evaluation of current economic and operating conditions, as well as assumptions regarding future events.

These events are, as at the date of this presentation, expected to take place, but there cannot be any guarantee that such will occur as anticipated, or at all, given that many of the events are outside Neurotech's control. The stated events may differ materially from results ultimately achieved. Accordingly, neither Neurotech nor any of its directors, employees, contractors or advisors make any warranty or assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this presentation will actually occur. Further, other than as required by law, Neurotech may not update or revise any forward-looking statement if events subsequently occur or information subsequently becomes available that affects the original forward-looking statement.

Disclaimer: Neither Neurotech nor its officers, employees, contractors or advisers make any warranty (express or implied) as to the accuracy, reliability, relevance or completeness of the material contained in this presentation. Nothing contained in this presentation is, or may be relied upon as a promise, representation or warranty, whether as to the past or the future. Neurotech excludes all warranties that can be excluded by law. Except for statutory liability which cannot be excluded, Neurotech, its officers, employees, contractors and advisers expressly disclaim any responsibility for the accuracy or completeness of the material contained in this presentation and exclude all liability whatsoever (including in negligence) for any loss or damage which may be suffered by any person as a consequence of any information in this presentation or any error or omission therefrom.

Professional advice: Recipients of this presentation should consider seeking appropriate professional financial, taxation and legal advice in reviewing the presentation and all other information with respect to Neurotech and evaluating its business, financial performance and operations.

Proprietary information and copyright: This presentation and the information it contains is proprietary to Neurotech. Neurotech holds the copyright in this presentation. Except as permitted under the Copyright Act 1968 (Australia), this paper or any part thereof may not be reproduced without its written permission.

Neurotech is a biopharmaceutical company focused on the development & commercialisation of neurological solutions that improve quality of life.



Exclusive worldwide licence



Extensive preclinical studies completed



World's first whole plant extract cannabis clinical study



PTC Patents lodged



Potential for NTI164 to treat neurological disorders



Neurotech's Mente device & therapy

Capital Structure

\$0.052

Share price
(as at 10 May 2022)

~\$36M

**Market
capitalisation**

~\$2.33M

Cash at bank*

696M

Share on issue

128M[^]

Options/rights



1. *as at COB 31 March 2022

2. ^Options are comprised at various strike prices between \$0.005 to \$0.09 as at 31 December 2021

Highly Experienced Executive Team and Board



Dr Alexandra Andrews
CEO

Expertise in corporate development, investor engagement, product development and commercialisation, clinical trials and regulatory environments.

Former Director of Operations at NeuroScientific Biopharmaceuticals Ltd.

PhD Neuroscience, BMed Sci (Hons1st)



Brian Leedman
Chairman

More than 15 years' experience in the biotechnology sector

Co-founder / Director / Chairman of six ASX listed healthcare/ biotechnology companies including: RAP, NGS, NSB, OSL, IMU, ALC

Former Chairman of Ausbiotech (WA)

BEd, MBA (UWA)



Krista Bates
Non-Executive Director

Experienced director of ASX and LSE companies

More than 20 years' experience in legal practice, specialising in mergers & acquisitions

Former Partner at leading law firm, Lavan Legal – Head of the Medicinal Cannabis Group

Founder, KB Corporate Advisors

BA(Hons), Grad Dip (Law), PostGrad Dip (Law), GAIDC



Prof. Allan Cripps AO
Non-Executive Director

Distinguished academic, clinical scientist and health services leader

Independent Chair of the Children's Health Research Alliance Board and Non-Executive Director at Bard1 (BD1)

Formerly the Pro Vice Chancellor (Health) at Griffith University and currently professor emeritus at Griffith University

PhD, BSc (Hons), FAHSM, FASM, FAIMS, FIBMS, FCHSM, MACID



Mark Davies
Non-Executive Director

More than 20 years' experience in trading, investment banking & providing corporate advice

Specialises in providing corporate advice & capital raising services to emerging companies seeking business development opportunities and funding from the Australian market

Managing Director of 1861 Capital and co-founder of investment banking firm, Cygnet Capital

BCom



Winton Willese
Non-Executive Director

Experienced company director with over 20 years experience in various roles within the Australian capital markets

Core expertise in strategy, company development, corporate governance, company public listings, merger and acquisition transactions and corporate finance

MCom, FFin, CPA, GAIDC, FGIA/FCG

What makes NTI164 different?

CBD/THC

VS

NTI164

- | | |
|--|---|
|  CBDA |  High CBDA |
|  Rare Cannabinoids |  Rarer Cannabinoids:
CBC, CBDP, CBDB, CBN, CBG |
|  Full Plant Extract |  Naturally >0.03% THC |
|  Entourage Effect |  >4% Terpenes |
|  Patent protected composition |  Entourage Effect |
| |  Patent pending (lodged Oct 2021) |
| |  Potent combination / Synergistic properties when combined with APIs |



Preclinical evidence from NTI164

Preclinical studies demonstrated:

- Reduction in brain cell inflammation (up to 60%)
- Increase in overall brain cell health and viability (in the absence of toxic insult up to 80%)
- Increase in mitochondrial viability and output (in the presence of toxic insult up to 60%)
- Significant suppression of neuro-markers linked to MS (GM-CSF < 40% and TNF-alpha < 30%)
- Multi-functional Mode of Action | neuro-protection, neuro-modulation and neuro-regulation



Why target Autism Spectrum Disorders (ASD)?

PREVALENCE OF ASD

~1 in 70 people in
Australia¹

~1 in 44 children
in the US²



RISPERIDONE
US\$5.6b³



US ANNUAL SALES
US\$2.1b⁴

Ritalin and Concerta
active ingredient Methylphenidate

TREATMENT
MARKET SIZE
US\$1.85b⁵

Since 2017, studies with medicinal
cannabis (CBD + THC) have shown
some promise in children with ASD

MARKET

ASD is a serious neuro
inflammatory developmental
disorder that impairs the ability
to communicate and interact

- Common symptoms include; behavioural issues, agitation, repetitive movements, inability to focus & compulsive neurological patterns

CURRENT TREATMENT

Huge unmet medical need
- patients need better
treatment

- Numerous side effects; Nausea, dry mouth, abdominal pain, restlessness, anxiety, irritability, insomnia, weight change, dizziness & heart palpitations

TRIALS

Until NTI – there had been no
previous trials assessing medicinal
cannabis with low (<0.3%) THC in
the treatment of ASD

- NTI has completed world first trial using whole plant (low THC) medicinal cannabis strain in children with ASD

NTI64

First in human Phase I/II ASD paediatric study (S8)

Commenced in May 2021 at Monash Children's Hospital led by A/Prof. Michael Fahey

- Open label – single group
- 20 patients from 8 to 17yo
- Dose ranging assessments (5, 10, 15 and 20 mg/kg)
- Interim results demonstrated safety & tolerability across dosing regime
- Assessments of behavioural marker analysis results
- No wash out period requested by Patients' parents and caretakers

Current and Future Opportunities for NTI164

AUTISM SPECTRUM DISORDER
US\$2.3b¹
Phase I/II to complete this quarter

MULTIPLE SCLEROSIS
US\$20b²
Preclinical studies in progress
Future Target

CEREBRAL PALSY
US\$4.4b³
by 2030
Future Target

ADHD
\$21b⁴
Future Target

MIGRAINE
US\$1.7b⁵
Future Target

TRAUMATIC BRAIN INJURY
US\$2.7b⁶
Future Target

COMBINATION THERAPIES
Prednisone
Diclofenac
& other

Strong Patent Position

Neurotech has lodged two strategic provisional patent applications with IP Australia to underpin future worldwide commercialisation in Neurological applications.

Composition

Uniqueness of the NTI-164 strain – composition profile with low THC (<0.3%) and a unique combination of ‘rarer’ cannabinoids:
CBDA, CBC, CBDP, CBDB & CBN

Lodged Oct 2021

Combination

The application, formulation and use of NTI164

Lodged Oct 2021

Pathways to Commercialisation

The anti-inflammatory properties NTI strains in combination with minimal presence of THC (< 0.3%) provides clear pathways to commercialisation:

Pharmaceutical

- FDA new drug registration
- Huge potential upside
- Partnering/licensing opportunities

Combination


- Fast route to commercialisation via the 505B2 route
- Combination with existing drugs i.e. Prednisone, Diclofenac, Celebrex

**GW Pharmaceuticals US\$7.2B
Acquisition by Jazz Pharmaceuticals¹**

Neurotech vs Peers

	Zelira Therapeutics Ltd	Neurotech International Ltd	Emyria Ltd	Little Green Pharma Ltd	Incannex Healthcare Ltd
Ticker	ZLD	NTI	EMD	LGP	IHL
Market Cap	A\$12M	A\$36M	A\$74M	A\$88M	A\$426M
Properties	CBD, CBD+THC	CBD-A, CBG, CBN, CBN-B, CBD-P	Low and High dose CBD	CBD, THC, TCH+CBD	CBD
Stage	Commercial	Phase I/II Clinical	Clinical	Clinical, Commercial	Clinical
Treatments	Insomnia & Autism	Autism & other Neurological Diseases	Psychological distress, IBS	N/A	OSA, IBS, Lung Inflammation, Rheumatoid Arthritis, Concussion, Anxiety
Source	Website	Internal	Website	Website	Website

NTI164 Development Program Timeline



Why Invest



**Experienced
board and
management**



**Unique
biopharmaceutical
cannabinoid
platform**



**Clinical
programs
underway
targeting pivotal,
unmet needs**



**Significant
near term
milestones
& newsflow**





Neurotech
International

Contact Details

Dr Alexandra Andrews
CEO

aa@neurotechinternational.com
+61 405 339 788

Brian Leedman
Chairman

b.leedman@neurotechinternational.com
+61 412 281 780

www.neurotechinternational.com
www.mentetech.com

Neurotech International Limited (ASX: NTI)